Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 9, 2014, Pages 1554-1557

  Greene, L A ^a   Law, C ^a   Jung, M ^a   Walton, S ^a   Ignjatovic, V ^b,c   Monagle, P ^b,c   Raffini, L J ^d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anticoagulants; Drug monitoring; Enoxaparin; Infant; Pediatrics; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN;

ANTI FACTOR XA ASSAY; ANTICOAGULATION; ARTICLE; ASSAY; CHILD; CLINICAL ARTICLE; CLINICAL LABORATORY; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; NEWBORN; OUTCOME ASSESSMENT; PATIENT MONITORING; PEDIATRICS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDIZATION; VALIDATION PROCESS; BLOOD EXAMINATION; CHEMISTRY; DRUG ADMINISTRATION; DRUG MONITORING; INFANT; PRESCHOOL CHILD; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY;

ANTICOAGULANTS; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ENOXAPARIN; FACTOR XA; FACTOR XA INHIBITORS; HEMATOLOGIC TESTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT; INFANT, NEWBORN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84908510977     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12641     Document Type: Article

References (11)

1. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124: 1001-8.
2. Punzalan RC, Hillery CA, Montgomery RR, Scott CA, Gill JC. Low molecular weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000; 22: 137-42.
3. Fung LS, Klockau C. Effects of age and weight-based dosing of enoxaparin on anti-factor Xa levels in pediatric patients. J Pediatr Pharmacol Ther 2010; 15: 119-25.
4. Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-G€ottle U, Vesely SK; American College of Chest Physicians. Antithrombotic therapy in children: antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 737S-801S.
5. Monagle P. We worry about our aim, when we don't even know the target. Thromb Res 2011; 127: 493.
6. Moharir MD, Shroff M, Stephens D, Pontigon AM, Chan A, MacGregor D, Mikulis D, Adams M, deVeber G. Anticoagulants in pediatric cerebral sinovenous thrombosis: a safety and outcome study. Ann Neurol 2010; 67: 590-9.
7. Tousovska K, Zapletal O, Skotakova J, Bukac J, Sterba J. Treatment of deep venous thrombosis with low molecular weight heparin in pediatric cancer patients: safety and efficacy. Blood Coagul Fibrinolysis 2009; 20: 583-9.
8. Kitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 2000; 11:137-44.
9. Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999; 21: 55-60.
10. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennett M, Horton S, Shann F, Lane G, Ross-Smith M, Monagle P. Monitoring unfractionated heparin (UFH) therapy:which anti-factor Xa assay is appropriate? Thromb Res 2007; 120: 347-51.
11. Nieuwenhuis HK, Albada J, Bangs J, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-43.